Clinical trial
A mulTi-center, Randomized, doUble-bliNded, Placebo-controlled Dose-escalating Study of the Effects of K201 on the RestorAtion of Sinus Rhythm in Subjects With Symptomatic Atrial Fibrillation of Recent Onset
NCT01259622 is registered in ClinicalTrials.gov with Sequel Pharmaceuticals, Inc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A mulTi-center, Randomized, doUble-bliNded, Placebo-controlled Dose-escalating Study of the Effects of K201 on the RestorAtion of Sinus Rhythm in Subjects With Symptomatic Atrial Fibrillation of Recent Onset
- Lead sponsor
- Sequel Pharmaceuticals, Inc
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- February 28, 2011
- Completion date
- December 31, 2011
- Enrollment
- 80 (estimated)
- Sites
- 17
Conditions
As the registry lists them; a condition with its own page is linked.